Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Arcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal

New follow-up results suggest Arcus’ drug might be superior to a marketed Merck medicine. Elsewhere, Eli Lilly and AstraZeneca forged new partnerships.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

Read the original at biopharmadive.com →

More in Health & Medicine

More from Wednesday 21 October →